-
公开(公告)号：US20090312236A1
公开(公告)日：2009-12-17
申请号：US12481111
申请日：2009-06-09
申请人： John Michael Beals , Gordon Butler Cutler, JR. , Brandon Doyle , Ryan John Hansen , Shun Li , Sean Shirani , Lianshan Zhang
发明人： John Michael Beals , Gordon Butler Cutler, JR. , Brandon Doyle , Ryan John Hansen , Shun Li , Sean Shirani , Lianshan Zhang
摘要： The present invention relates to the field of diabetes. More particularly, the invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene glycol), are highly soluble at physiological pH, have an extended duration of action, and characterized by pharmacokinetic, pharmacodynamic, and/or activity peak-trough ratios of less than 2. The invention also relates to methods of providing such molecules, to pharmaceutical compositions containing them, and to their therapeutic uses.
摘要翻译： 本发明涉及糖尿病领域。 更具体地，本发明涉及用高分子量聚（乙二醇）聚乙二醇化的聚乙二醇化的赖脯胰岛素化合物，在生理pH下是高度可溶的，具有延长的作用持续时间，并且其特征在于药代动力学，药效学和/或活性峰 通过比例小于2.本发明还涉及提供此类分子的方法，含有它们的药物组合物及其治疗用途。
-
公开(公告)号：US20110105392A1
公开(公告)日：2011-05-05
申请号：US12997254
申请日：2009-06-09
申请人： John Michael Beals , Gordon Butler Cutler, JR. , Brandon Lee Doyle , Ryan John Hansen , Shun Li , Shahriar Shirani , Lianshan Zhang
发明人： John Michael Beals , Gordon Butler Cutler, JR. , Brandon Lee Doyle , Ryan John Hansen , Shun Li , Shahriar Shirani , Lianshan Zhang
摘要： The present invention relates to the field of diabetes. More particularly, the invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene glycol), are highly soluble at physiological pH, have an extended duration of action, and characterized by pharmacokinetic, pharmacodynamic, and/or activity peak-trough ratios of less than 2. The invention also relates to methods of providing such molecules, to pharmaceutical compositions containing them, and to their therapeutic uses.
摘要翻译： 本发明涉及糖尿病领域。 更具体地，本发明涉及用高分子量聚（乙二醇）聚乙二醇化的聚乙二醇化的赖脯胰岛素化合物，在生理pH下是高度可溶的，具有延长的作用持续时间，并且其特征在于药代动力学，药效学和/或活性峰 通过比例小于2.本发明还涉及提供此类分子的方法，含有它们的药物组合物及其治疗用途。
-
公开(公告)号：US20100015155A1
公开(公告)日：2010-01-21
申请号：US12521309
申请日：2008-01-09
申请人： Kelly Renee Bales , Thomas Frank Bumol , Chi-Kin Chow , Ronald Bradley Demattos , Ryan John Hansen , Uma Kuchibhotla , Jirong Lu , Peter Colon McDonnell
发明人： Kelly Renee Bales , Thomas Frank Bumol , Chi-Kin Chow , Ronald Bradley Demattos , Ryan John Hansen , Uma Kuchibhotla , Jirong Lu , Peter Colon McDonnell
IPC分类号： A61K39/395 , C07K16/00 , A61P25/28
CPC分类号： C07K16/18 , A61K47/60 , A61K47/6893 , A61K2039/505 , A61K2039/6093 , B82Y5/00 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2319/31 , Y10S530/866
摘要： A method to treat conditions associated with Aβ peptide activity both prophylactically and therapeutically is described. The method employs humanized antibody fragments that specifically bind human Aβ peptide between amino acid positions 13-28, wherein the antibody fragments are covalently attached to a polyethylene glycol (PEG) molecule.
摘要翻译： 描述了一种治疗与预防和治疗双重肽活性相关的病症的方法。 该方法使用在氨基酸位置13-28之间特异性结合人Abeta肽的人源化抗体片段，其中抗体片段共价连接到聚乙二醇（PEG）分子上。
-
公开(公告)号：US09050371B2
公开(公告)日：2015-06-09
申请号：US12481111
申请日：2009-06-09
摘要： The present invention relates to the field of diabetes. More particularly, the invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene glycol), are highly soluble at physiological pH, have an extended duration of action, and characterized by pharmacokinetic, pharmacodynamic, and/or activity peak-trough ratios of less than 2. The invention also relates to methods of providing such molecules, to pharmaceutical compositions containing them, and to their therapeutic uses.
摘要翻译： 本发明涉及糖尿病领域。 更具体地，本发明涉及用高分子量聚（乙二醇）聚乙二醇化的聚乙二醇化的赖脯胰岛素化合物，在生理pH下是高度可溶的，具有延长的作用持续时间，并且其特征在于药代动力学，药效学和/或活性峰 通过比例小于2.本发明还涉及提供此类分子的方法，含有它们的药物组合物及其治疗用途。
-
-
-
搜索结果
4 条记录 (耗时 0.013 秒)
